Navigation Links
Moffitt-USF head toward first human trials of anti-cancer drug that targets protein AKT

H. Lee Moffitt Cancer Center & Research Institute, working in partnership with the University of South Florida (USF), has discovered a new use for an old, previously discredited anti-cancer drug that could add another weapon in the arsenal against several cancers, including tumors of the breast, ovary, colon, skin and prostate.

The compound, tricirbine, was tested at various cancer centers from 1982 to 1996 and found to inhibit some cancers, but researchers failed to determine why. The Moffitt-USF team discovered that tricirbine works only against tumors in which the cancer-causing Akt protein is abundant and/or abnormally active.

"These tumors are addicted to hyperactive Akt and cannot survive without it," explains Saïd Sebti, Ph.D., Moffitt's Manuel and Adeline Garcia Professor, Leader of the Drug Discovery Program and Associate Director of Moffitt Research Institute. "What we discovered is a tailored therapy for tumors with a specific molecular signature."

Resurrecting tricirbine may be promising for patients with ovarian cancer, for instance, because "40 percent of women with ovarian cancer have tumors with high levels of active Akt," according to Sebti.

"To our knowledge, this is the first Akt inhibitor headed toward clinical trials," said Jin Cheng, MD, PhD, USF Professor of Pathology and Interdisciplinary Oncology.

Cheng and Sebti's study results were published in the journal Cancer Research.

VioQuest Pharmaceuticals Inc. (VQPH) of New Jersey is acquiring the licensing rights to the compound from USF through its merger with Greenwich Therapeutics Inc. and is planning clinical trials with Moffitt. The trials are expected to start within six to eight months. Patients will be selected for the trials based on whether their tumors have hyperactive Akt, which can be determined by a simple slide-stain test of tumor tissue.

Because tricirbine has previously been investigated in humans, the hypothesis-driven c linical trials planned at Moffitt can move directly into a PhaseI/II trial.

With the step-up of functional-genomics research at Moffitt and around the country, the advent of "customized medicine" has been heralded in headlines and at medical conferences. The clinical trial of this Akt-inhibitor is a concrete step toward that reality. Sebti says, "The beauty of this trial is that it's molecular therapy, based on the blueprint of the tumor cell."


'"/>

Source:University of South Florida Health Sciences Center


Related biology news :

1. Unchecked DNA replication drives earliest steps toward cancer
2. Virologists make major step towards understanding the process of HIV infection
3. Cats indifference towards sugar explained
4. A step toward the $1,000 personal genome using readily available lab equipment
5. A new step towards an AIDS vaccine
6. New GM mosquito sexing technique is step towards malaria control, report scientists
7. Novel method reveals how menthol discovery could point towards new or improved pain therapies
8. Scientists make first step towards holy grail of crystallography
9. Salk researchers make fast strides towards understanding how our body controls walking
10. Illegal trade is propelling rare turtle toward extinction, new report
11. Iraqs marshes show progress toward recovery
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/7/2018)... ... September 06, 2018 , ... Sensors Midwest (#SensorsMW18), ... Sensors Expo & Conference , announces their partnership with Fraunhofer USA Center ... IoT Enabled Industrial IoT Certification Program. Taking place on October 17, 2018 at ...
(Date:9/1/2018)... ... 31, 2018 , ... Right this minute, Frenchman Ben Lecomte is hard at work on his ... he’s taken on a new challenge: going from Tokyo to San Francisco, churning his limbs ... on the support boat. As the first expedition of its kind, The Swim is far ...
(Date:8/31/2018)... ... August 30, 2018 , ... CallTower is pleased to ... than 20-years of telecommunications experience and over ten years in executive leadership. Prior to ... by CallTower in early 2018. , In this new role, Jason ...
Breaking Biology News(10 mins):
(Date:8/21/2018)... ... ... The Connecticut Technology Council (CTC) and Marcum LLP today announce the 2018 ... Connecticut. This year’s group of top-ranked companies will be honored at the new ConnectiTECH ... in Hartford. A complete list of the Marcum Tech Top 40 is included below. ...
(Date:8/17/2018)... ... August 16, 2018 , ... KCAS Bioanalytical ... announce the expansion of their team. Dr. Dawn Dufield, Ph.D., joins KCAS as ... large molecule LC-MS/MS group that will specialize in developing quantitative LC-MS/MS assays for ...
(Date:8/17/2018)... Columbia (PRWEB) , ... August 17, 2018 , ... ... International Society for Biological and Environmental Repositories (ISBER) is pleased to announce the ... , The Fourth Edition publication, originally released in January 2018, is a practice-changing ...
(Date:8/14/2018)... ... August 14, 2018 , ... Buprenorphine ... use disorder. BUP is often prescribed as a sublingual co-formulation with the opioid ... this webinar, participants will learn from a review of the pharmacokinetics of BUP, ...
Breaking Biology Technology: